natgillin/translations-raw huggingface dataset:
to provide a compound of the formula (II): 
(D kako bi se dobio spoj formule (II):
represents a number of R4 and is an integer of 0 to 6; 
predstavlja broj od R4 i cijeli je broj od 0 do 6;
The process according to claim 1, wherein the mineral preparation has a water content of from 15 to 60 wt.-%, of the total weight of the preparation. 
Uporaba prema bilo kojem od zahtjeva 12 do 14, naznačena time da vodeni pripravak ima sadržaj vode od 15 do 60 wt-%, poželjnije od 18 do 55 wt-%, posebno od 20 do 30 wt-%, naročito od 22 do 28 wt-%, npr. 25 wt-% od ukupne mase pripravka.
A compound of formula (II): or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: 
Spoj s formulom: ili njegova farmaceutski prihvatljiva sol ili stereoizomer.
The aqueous portion is filtered over Hyflo Supercel® to remove particulate matter from the enzyme and the filter aid cake washed with 0.75 M KH2PO4 buffer (1280 mL, 0.9 vol) that has been pH adjusted to 7.5 with 5 N NaOH. 
Vodeni dio filtrira se kroz Hyflo Supercel? kako bi se se uklonilo čestice od enzima, a filtarski kolač ispere 0,75 M KHL,PO, puferom (1280 ml, 0,9 vol. ekv.), pH podešenog na 7,5 s 5 N NaOH.
Rheumatic diseases/autoimmune diseases/joint diseases, which coincide with inflammatory, allergic and/or proliferative processes: 
(ii) reumatske bolesti ii autoimune bolesti ili bolesti zglobova, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
A compound according to claim 1, selected from the following compound and pharmaceutically acceptable salts, solvates, and hydrate thereof: 
Pripravak u skladu sa zahtjevom 1, naznačen time, da: spoj je izabran među slijedećim spojem i njegovim farmaceutski prihvatljivim solima, solvatima i hidratima:
A process for the production of an anti-FcRn antibody or FcRn-binding fragment thereof, comprising culturing the host cell of claim 12 and isolating the anti-FcRn antibody or FcRn-binding fragment. 
Proces za proizvodnju antitijela koje se specifično vezuje za ljudski FcRn, koji se sastoji od uzgajanja domaćinske stanice prema patentnom zahtjevu 16 i izoliranja antitijela.
A pharmaceutical composition characterized by comprising at least one of the antibodies or functional fragments of the antibodies according to claims 1 to 18, and 30 to 32. 
Farmaceutska kompozicija naznačena time da sadrži najmanje jedno od antitijela ili funkcionalnih fragmenata antitijela prema patentnim zahtjevima 1 do 21.
The process according to any one of claims 1 to 5, wherein the said at least one curing agent component (b2) is a JEFFAMINE® XTJ polyetheramine, which is a primary amine with the terminal end group of the formula prepared by amination of butylene oxide capped alcohols. 
Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time što je navedeno najmanje jedno sredstvo za stvrdnjavanje komponenta (b2) JEFFAMINE& XTJ polieteramin, koji je primarni amin s terminalnom završnom skupinom s formulom T NH, CH.
Preferably, the compositions are characterized by a breakdown of less than 2.5% pinoxaden after 2 weeks storage at a temperature of 50° C. A preferred composition according to the present invention contains 
Pripravak prema zahtjevu 1 ili zahtjevu 2 koji je naznačen time da ima raspadanje od manje od 2.5% pinoksadena nakon 2 tjedna skladištenja na temperaturi od 50*C.
The monoclonal antibody or antigen binding fragment thereof of claim 1 which binds to at least five CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL15/HCC-2, and CCL23/MPIF-1, and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje pet CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL15/HCC-2, i CCL23/MPIF-1, i koji se ne veže na CCL2/MCP-1.
The pharmaceutical composition of any of items 1 to 16, wherein at least one of said first or second binding domains is chimeric, humanized, CDR-grafted, and/or deimmunized or human. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačen time što je najmanje jedna od navedene prve ili druge vežuće domene kimerna, ljudskiizirana, nazađena s CDR-om i/ili deimunizirana ili ljudska.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the composition comprises at least: 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 11, naznačen time da pripravak sadrži najmanje:
Best overall response (73) 
(73) Nositelj patenta:
reacting the compound of the Formula IX with a compound of the Formula II as defined above in the presence of a suitable base to provide a compound of the Formula X or a salt thereof; 
2-N G-0-$ CH, lI u prisutnosti pogodne baze sa svrhom dobivanja spoja sa formulom X ili njegove soli;
The concentration ratio (food/extract) in the stages of Microfiltration, Ultrafiltration, Nanofiltration and Inverse Osmosis is preferably higher than 8. 
Postupak prema patentnom zahtjevu 1, naznačen time da je omjer koncentriranja (unos/ekstrakt) u koraku a) veći od 8.
allowing the antibody to bind to the amyloid protein to form an immunological complex; 
(b) omogućavanju da se protutijelo veže na amiloidni protein kako bi tvorilo imunološki kompleks;
The composition for the use according to claim 19 or claim 20, wherein (1) is a compound of the formula: 
Spoj bilo kojeg od patentnih zahtjeva 1-14 gdje A15 je odabrano od: [image]
The capsule of claim 12 wherein the surfactant is one of sodium lauryl sulphate, polyoxyethylene polyoxypropylene glycol, polyethylene glycol, poplypropylene glycol, polyvinyl caprolactam—polyvinyl acetate—polyethylene glycol, macrogolglycerol hydroxystearate or combinations thereof. 
Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 15, naznačena time što se površinski aktivna tvar sastoji od natrijeva lauril-sulfata, polioksietilen polioksipropilen glikola, polietilen glikola, polipropilen glikola, polivinil kaprolaktama-polivinil acetata-polietilen glikola, makrogolglicerol hidroksistearata ili kombinacija navedenog.
The ether solution was washed with water (3 x 50 ml.), dried (MgSO4), filtered and evaporated under vacuum to an oil. 
Eterska otopina se ispere s vodom (3 x 50 ml), suši se (MgSOx), filtrira i ispari u vakuumu do ulja.
The composition of any of claims 6-8, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier. 
Sastav prema bilo kojem od patentnih zahtjeva 6-8, naznačen time, da sastav jest farmaceutski sastav, a nosilac jest farmaceutski prihvatljivi nosilac.
In a further embodiment, the present invention also relates to use of a compound of formula I for the preparation of a medicament for the treatment of anxiety disorders. 
U daljnjoj verziji, ovaj izum se odnosi i na uporabu spoja formule I za pripravu lijeka za liječenje poremećaja tjeskobe.
applying a sufficient amount of a first granular material over the first geogrid layer and then compacting the first granular material to form a first granular layer that has an average thickness of from 0.5 times to 20 times an aperture distance of the geogrid layer; 
primjenu dovoljne količine prvog granuliranog materijala preko prvog sloja geomreže i zatim sabijanje prvog granuliranog materijala da nastane prvi sloj granulata (70) koji ima prosječnu debljinu od 0.5 puta do 20 puta udaljenosti otvora sloja geomreže;
An electrically heated smoking system according to claim 1 or 2, wherein the one or more electrically conductive tracks are on the outside of the tubular electrically insulating substrate. 
Električno grijani sustav za pušenje u skladu s patentnim zahtjevom 1, 2 1li 3, naznačen time što se jedna ili više električno vodljivih tračnica (203) nalazi s vanjske strane cijevi od električno izolirajuće podloge (201).
The apparatus set forth any of claims 1 - 6 wherein said first and second drive gears have tapered polygonal openings, and wherein said drive shaft has tapered polygonal ends received in said tapered polygonal openings of said first and second drive gears. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 - 6, naznačen time što navedeni prvi i drugi pogonski zupčanici imaju višekutni otvor koji se sužava i što navedena pogonska osovina ima višekutne krajeve koji se sužavaju i koji se prihvaćaju u navedene višekutne otvore koji se sužavaju navedenog prvog i drugog pogonskog zupčanika.
Fig. 2 shows a state in which such a capsule has been placed on a capsule holder 13, the foil member 5 resting on the relief element 12 side of the capsule holder 13 and the cup-like base body 4 of the capsule 1 being already partly surrounded by the circumferential wall 25 of an enclosing member 9 of the beverage production device. 
Slika 2 prikazuje položaj u kojemu je takva čahura bila stavljena na držač čahure 13, pri čemu je element od folije 5 položen na stranu reljefnog elementa 12 držača čahure 13, a baza tijela 4 koje ima oblik čašice 1 je već djelomično okružena obodnom stijenkom 25 elementa koji obuhvaća čahuru 9 uređaja za pripremanje napitka.
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 6, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37°C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema bilo kojem zahtjevu od 1 do 5, gdje formulacija matrice s produljenim otpuštanjem nakon što je skladištena na 25°C i 60 % relativne vlažnosti (RH) najmanje 1 mjesec daje stupanj otapanja, kada je mjerenje obavljeno u USP aparatu 1 (koš) pri 100 rpm u 900 ml simulirane želučane tekućine bez enzima (SGF) pri 37°C, naznačen time da postotak količine oslobođenog aktivnog agensa u 1,4 i 12 sati otapanja nema odstupanje više od oko 15 % točaka u odnosu na odgovarajući in-vitro stupanj otapanja referentne formulacije prije skladištenja.
The compound of claim 1 where in the amino ester is selected from the group consisting of an amino ester, a cyclic amino ester and an acylated amino ester. 
Spoj koji ima formulu: naznačen time, da je R, odabran iz skupine koju čine pegilirani ester, hidroksilirani ester, razgranani hidroksilirani ester i pegilirani ester pomiješan s oksalnom kiselinom.
Therefore, the present invention also relates to a CD19xCD3 bispecific single chain antibody construct as defined herein for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL). 
CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt, naznačeno time što je namijenjeno upotrebi u postupku liječenja, ublažavanja ili otklanjanja pedijatrijske akutne limfoblastične leukemije (ALL) kod pedijatrijskog pacijenta s ALL.
The process of claim 3, wherein said carboxylic acid is benzoic acid. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedena karboksilna kiselina je benzojeva kiselina.
The composition for use of any one of claims 1 to 5, wherein the composition comprises a salt of the compound represented by The composition for use of any one of claims 1 to 6, wherein the composition further comprises a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži terapeutski efikasnu količinu spoja prema patentnim zahtjevima 1 do 5 u kombinaciji sa farmaceutski prihvatljivim nosačem ili ekscipijensom. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5 za uporabu u liječenju HBV.
The dental post according to claim 3, characterized in that said X-ray absorbing material comprises a mineral filler comprising a chemical compound with an element of an atomic number of at least 37, more preferred of at least 57, in particular ytterbium. 
Zubni most u skladu s patentnim zahtjevom 3, naznačen time što navedeni materijal koji apsorbira rendgensko zračenje sadrži mineralno punilo koje sadrži kemijski spoj s elementom s atomskim brojem od najmanje 37, poželjnije od najmanje 57, osobito iterbijem.
Maltitol has a sweetness that is equal to about 90 % of the sweetness of sucrose. 
Maltitol posjeduje slatkoću koja iznosi 90 % slatkoće saharoze.
A method for controlling damaging insects of plants, crops or seeds comprising the application of an agronomically effective and substantially non-phytotoxic quantity of a pesticide composition according to any one of claims 1 to 5 as seed treatment, foliar application, stem application, drench or drip application or chemigation to the seed, the plant or to the fruit of the plant or to soil or to inert substrate, Pumice, Pyroclastic materials or stuff, synthetic organic substrates organic substrates or to a liquid substrate wherein the plant is growing or wherein it is desired to grow. 
Postupak za suzbijanje fitopatogenih gljiva kod biljaka, usjeva ili sjemena, naznačen time da obuhvaća primjenu agronomski učinkovite i uglavnom nefitotoksične količine pripravka pesticida u skladu s bilo kojim od patentnih zahtjeva 1 do 11 kao sredstva za tretiranje sjemena, folijarnu primjenu, primjenu na stabljike, primjenu namakanjem ili kapanjem ili kemigacijom na sjeme, biljke ili na plod biljke ili na tlo ili na inertni supstrat, kamen plavac, piroklastične materijale 1li sredstva, sintetičke organske supstrate organskih supstrata ili na tekući supstrat pri čemu biljka raste ili pri čemu se želi da biljka raste.
Heteromolecular metal complexes (chelates) disclosed in the preceding claims, which contain the following mineral nutrients: nitrogen, potassium, phosphorus, calcium, magnesium and any trace element. 
Heteromolekularni metalni kompleksi (kelati) otkriveni u prethodnim zahtjevima, naznačeni time što sadrže slijedeće mineralne hranjive tvari: dušik, kalij, fosfor, kalcij, magnezij 1 bilo koje elemente u tragovima.
contacting the boron "ate" complex of formula (II) with a Lewis acid in a solution comprising an ether solvent that has low miscibility with water to form the boronic ester compound of formula (I), wherein the solubility of water in the ether solvent that has low miscibility with water is less than 5% w/w. 
otapalo koje ima nisku mješavost sa vodom da bi sc formiralo spoj cstcr organobornc kiseline formule (7), pri čemu je otopljivost vode u eterskom otapalu kojei ima nisku mješavost sa vodom manja od 5% tež./tež. 33.
The compound according to claim 1, wherein the compound is defined by a and c being a single bond, b being a double bond, and R2 being OR5, OR5 being as defined in claim 1. 
Spoj za uporabu prema zahtjevu 1, gdje je spoj definiran time što su a i c jednostruka veza, b je dvostruka veza.
The unit dosage form of claim 1, wherein the pharmaceutical composition is in a hermetically sealed container selected from the group consisting of a vial, a sachette, a pre-filled syringe, a pre-filled autoinjector, a cartridge for a reusable syringe, and an applicator. 
Farmaceutski pripravak za uporabu u skladu s jednim od patentnih zahtjeva 1 do 11, naznačen time da oblik jediničnog doziranja sadrži protutijelo ili njegov fragment koji veže antigen kao tekuću formulaciju i u hermetički zatvorenoj posudi odabranoj iz skupine koju čine bočica, vrećica, prethodno napunjena štrcaljka, prethodno napunjeni autoinjektor, uložak za višekratnu štrcaljku, i aplikator.
A method of treating a disease related to abnormal activities of JAK3 and/or JAK1 kinases in a human patient, comprising administering the human patient the pharmaceutical composition according to claim 15, wherein the disease related to abnormal activities of JAK3 and/or JAK1 kinases is selected from the group consisting of rheumatoid arthritis, psoriasis, systemic lupus erythematosus, multiple sclerosis, type I diabetes, leukaemia, and lymphoma. 
Korištenje farmaceutskog sastava prema zahtjevu 11 u pripremi lijeka za liječenje ili prevenciju autoimunih bolesti, upalnih bolesti, rakova, mijeloproliferativnih bolesti, bolesti resorpcije kosti, bolesti presatka protiv primatelja, reumatoidnog artritisa, psorijaze, Crohnove bolesti, sistemskog eritemskog lupusa, multiple skleroze, tip I dijabetesa, alergijskih bolesti, kronične opstruktivne plućne bolesti, astme, leukemije i limfoma.
applying a solution comprising poly (ethylene glycol) having a concentration of about 10% by weight and glycine having a concentration of about 4% to 8% by weight to the cation exchange chromatography material, thereby separating the antibody of the IgG class in monomeric form with reduced host cell protein content from the antibody in aggregate form and obtaining the antibody in monomeric form with reduced host cell protein content. 
proizvodnja protutijela IgG-razreda u monomernom obliku primjenom otopine koja sadrži poli(etilenglikol) i sorbitol na kromatografski materijal, te time desorbiranje / eluiranje protutijela IgG-razreda u monomernom obliku iz kromatografskog materijala, pri čemu poli(etilenglikol) ima koncentraciju od 10 masenih % i sorbitol ima koncentraciju od 5 masenih % do 20 masenih %.
The use of a combination as claimed in any one of claims 1-13 in the manufacture of a medicament for the treatment of cancer, in a warm-blooded animal, such as man. 
Uporaba spoja prema bilo kojem od patentnih zahtjeva 1-13 u proizvodnji lijeka za liječenje raka, u toplokrvnoj životinji, poput čovjeka.
The combined aqueous layers was carefully acidified with conc. 
Kombinirani vodeni sloj je pažljivo zakiseljen sa konc.
The method of claim 1, the prodrug compound is represented by a structure of Formula 2 or stereoisomer thereof or pharmaceutically acceptable salt thereof 
Sastav iz patentnog zahtjeva prihvatljivu sol. 1, tvar sadrži strukturu Formule 2 ili njen stereoizomer ili njenu farmaceutski
The long term treatment usually comprises daily administration of the medicament for an extended period of time, e.g. for at least two weeks, preferably for at least 4 weeks, more preferably for at least 8 weeks, even more preferably for at least 12 weeks, and most preferably for at least 6 months or at least 12 months. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu se navedeno liječenje primjenjuje jednom dnevno kroz najmanje četiri tjedna, kroz najmanje osam tjedana, kroz najmanje dvanaest tjedana ili kroz najmanje dvanaest mjeseci.
In the foregoing method, the step of exposing is preferably chosen from the options of: bringing said coating composition (I) into close proximity with said relief surface of said magnetic plate; and bringing a second surface of the substrate (S), opposite to the said first surface carrying said coating composition (I), into contact with said relief surface of said magnetic plate. 
Postupak sukladno patentnom zahtjevu 13 ili patentnom zahtjevu 14, naznačen time, da je korak izlaganja odabran između sljedećih mogućnosti: postavljanje navedenog materijala za premazivanje (I) vrlo blizu navedene reljefne površine navedene magnetske ploče; te postavljanje druge površine podloge (5), koja se nalazi nasuprot navedene prve površine s navedenim materijalom za premazivanje (1), tako da dodiruje navedenu reljefnu površinu navedene magnetske ploče.
A solid system for the modified release in accordance with any of claims 1-5, wherein the active ingredients comprise vitamins, aminoacids, minerals, pharmacologically active ingredients, plant extracts, phytocompounds, probiotic microorganisms and mixtures thereof. 
Čvrsti sustav za modificirano oslobađanje u skladu sa bilo kojim od patentnih zahtjeva 1-5, naznačen time što aktivni sastojci sadrže vitamine, aminokiseline, minerale, farmakološki aktivne sastojke, biljne ekstrakte, fito-spojeve, probiotičke mikroorganizme i njihove smjese.
Such conditions include, in particular, pain, e.g., bone and joint pain (osteoarthritis), cancer pain, myofascial pain (muscular injury, fibromyalgia) and perioperative pain (general surgery, gynecologic surgery). 
Takva stanja uključuju, u posebno, bol, npr. bol kosti i zgloba (osteoartritis), bol raka, miofascijalnu bol (ozljeda mišića, fibromijalgija) i perioperativnu bol (opća kirurgija, ginekološka kirurgija).
1 (I) and (III) by maintaining an aqueous reaction mixture comprising excess pyrophosphate and a platinum complex of the formulas shown in FIG. 
(i) održavanje vodene reakcijske smjese koja sadrži višak pirofosfata i kompleks platine prema formuli V ili VI: HR P20140808 T1
For example, if 42-O-(4-nitrophenyloxycarbonyl)rapamycin (an activated rapamycin) is reacted with a sugar the result is a rapamycin carbohydrate derivative wherein the 42-hydroxyl oxygen of rapamycin is covalently bonded to a carbonyl group which in turn is covalently bonded to a hydroxyl oxygen on the sugar. 
Na primjer, ako 42-O-(4-nitrofeniloksikarboniljrapamicin (aktivirani rapamicin) reagira sa šećerom, rezultat je ugljikohidratni derivat rapamicina u kojem je 42-hidroksilni kisik rapamicina kovalentno vezan na karbonilnu grupu koja je u natavku kovalentno vezana na hidroksilni kisik šećera.
Another embodiment includes a method of manufacturing and recovering a protein of interest wherein the protein of interest is rFVIII comprising: recombinantly producing a protein of interest using a host cell within a medium; filtering the medium using depth filtration with a positive charge; exposing the positively charged depth filter to a salt elution buffer to release protein of interest from the filter; recovering released protein of interest from the elution buffer; and recovering further protein of interest from the sample passed through the depth filter, wherein the elution buffer is a salt elution buffer and has a conductivity of at least 20 mS/cm. 
Metoda za proizvodnju i obnavljanje proteina od interesa obuhvaća: rekombinantnu proizvodnju proteina od interesa koristeći stanicu domaćina unutar medija; filtriranje medija koristeći dubinski filtar s pozitivnim nabojem; izlaganje pozitivno nabijenog dubinskog filtra soli elucijskog pufera zbog oslobađanja proteina od interesa iz filtra, pri čemu sol elucijskog pufera ima provodljivost od najmanje 20 mS/em; obnavljanje oslobođenog proteina od interesa iz elucijskog pufera; obnavljanje daljnjeg proteina od interesa iz uzorka koji je prošao kroz dubinski filtar.
The composition of claim 10, wherein the solubilized cortexolone-17a-propionate is present in the composition in a concentration of from 0.1 to 2% by weight of the composition. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što je spoj Formule IIa prisutan u količini od 0,025 mol.
A process for conjugating a bacterial saccharide comprising the steps of reacting the bacterial saccharide with 0.001-0.7, 0.005-0.5, 0.01-0.5, 0.1-0.5 or 0.1-0.2 molar equivalents of periodate to form an activated bacterial saccharide; 
PATENTNI ZAHTJEVI Postupak konjugiranja bakterijskog saharida, naznačen time što obuhvaća korake: a) reakcije bakterijskog saharida s 0,001-0,7 molarnih ekvivalenata perjodata kako bi se dobio aktivirani bakterijski saharid; b) miješanja aktiviranog bakterijskog saharida s proteinskim nosačem;
In general sunstruck formation in beer is promoted particularly strongly by light with a wavelength of 250-550 nm. 
Općenito, užeglu aromu kod piva naročito snažno potiče svjetlo valne duljine od 250-550 nm.
Clause 20. The antisense oligonucleotide of clause 19, wherein the sugar moieties of the backbone are replaced with non-natural moieties. 
Antisens oligonukleotid u skladu sa zahtjevom 3, naznačen time što šećerni ostaci u oligonukleotidnoj okosnici su zamijenjeni neprirodnim ostacima.
the heat transport fluid comprises a liquid phase and a gas phase within the fluid conduit, and by: arranging for passive flow within the fluid conduit. The method of claim 11, wherein: 
naznačen time, da fluid za prijenos topline obuhvaća tekuću fazu i plinovitu fazu unutar fluidnog cjevovoda, te time, da se raspoređuje za pasivni protok unutar fluidnog cjevovoda.